Iterum Therapeutics PLC (ITRM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.00 (-99.68%), Market cap $0.00B, 52-week low–high $0.01 ~ $1.26.
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as w
Financial statements, price targets, institutional (13F) holdings and related news for Iterum Therapeutics PLC are updated in real time on BlackAll Trade.
Iterum Therapeutics PLC trades at $0.00 (-99.68%). Real-time quotes and charts are available on BlackAll Trade.
Iterum Therapeutics PLC has a market cap of about $0.00B.
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVA